NWF Advisory Services Inc. Has $469,000 Stake in GRAIL, Inc. $GRAL

NWF Advisory Services Inc. reduced its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 58.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,081 shares of the company’s stock after selling 12,989 shares during the quarter. NWF Advisory Services Inc.’s holdings in GRAIL were worth $469,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Perigon Wealth Management LLC raised its position in GRAIL by 0.7% in the 4th quarter. Perigon Wealth Management LLC now owns 19,450 shares of the company’s stock worth $1,665,000 after purchasing an additional 133 shares during the last quarter. Parallel Advisors LLC lifted its holdings in GRAIL by 5.2% during the 4th quarter. Parallel Advisors LLC now owns 2,667 shares of the company’s stock worth $228,000 after buying an additional 133 shares in the last quarter. Westmount Partners LLC boosted its position in GRAIL by 1.8% in the 4th quarter. Westmount Partners LLC now owns 8,279 shares of the company’s stock valued at $709,000 after buying an additional 150 shares during the last quarter. Comerica Bank boosted its position in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after buying an additional 173 shares during the last quarter. Finally, Whittier Trust Co. increased its stake in shares of GRAIL by 19.3% in the 4th quarter. Whittier Trust Co. now owns 1,114 shares of the company’s stock valued at $95,000 after buying an additional 180 shares during the period.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Several plaintiff firms reiterated class-action and lead-plaintiff deadlines for investors who bought GRAL shares between May 13, 2025 and February 19, 2026, keeping the lawsuit in focus. Article Title
• Neutral Sentiment: The filings reinforce that the suit centers on alleged misrepresentations about NHS-Galleri trial results and a major post-news stock decline, which remains the main investor concern. Article Title
• Negative Sentiment: The concentration of lawsuits and deadline reminders increases legal overhang and could keep pressure on GRAIL shares until more clarity emerges on the case. Article Title

GRAIL Price Performance

GRAIL stock opened at $73.12 on Wednesday. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of -7.05 and a beta of 3.22. The company’s 50 day simple moving average is $65.01 and its 200 day simple moving average is $69.58. GRAIL, Inc. has a fifty-two week low of $29.95 and a fifty-two week high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, beating the consensus estimate of ($2.76) by $0.47. The firm had revenue of $40.78 million during the quarter, compared to the consensus estimate of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. As a group, analysts predict that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GRAL. Piper Sandler boosted their target price on GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. The Goldman Sachs Group started coverage on GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target on the stock. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Mizuho began coverage on GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective for the company. Finally, Wolfe Research assumed coverage on shares of GRAIL in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $67.00.

Insider Activity

In other news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares of the company’s stock, valued at $10,001,117.04. The trade was a 0.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.83% of the stock is owned by company insiders.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.